HK1127912A1 - 神經酰胺和化療藥物引致細胞死亡 - Google Patents

神經酰胺和化療藥物引致細胞死亡

Info

Publication number
HK1127912A1
HK1127912A1 HK09107139.8A HK09107139A HK1127912A1 HK 1127912 A1 HK1127912 A1 HK 1127912A1 HK 09107139 A HK09107139 A HK 09107139A HK 1127912 A1 HK1127912 A1 HK 1127912A1
Authority
HK
Hong Kong
Prior art keywords
ceramide
cell death
chemotherapeutic agents
inducing cell
inducing
Prior art date
Application number
HK09107139.8A
Other languages
English (en)
Inventor
Harold J Wanebo
Shashikant Mehta
Original Assignee
Roger Williams Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roger Williams Hospital filed Critical Roger Williams Hospital
Publication of HK1127912A1 publication Critical patent/HK1127912A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK09107139.8A 1999-04-07 2009-08-04 神經酰胺和化療藥物引致細胞死亡 HK1127912A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/287,884 US7820718B1 (en) 1999-04-07 1999-04-07 Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer

Publications (1)

Publication Number Publication Date
HK1127912A1 true HK1127912A1 (zh) 2009-10-09

Family

ID=23104788

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09107139.8A HK1127912A1 (zh) 1999-04-07 2009-08-04 神經酰胺和化療藥物引致細胞死亡

Country Status (6)

Country Link
US (2) US7820718B1 (zh)
EP (2) EP2020237B1 (zh)
AU (1) AU4335400A (zh)
DK (1) DK2020237T3 (zh)
HK (1) HK1127912A1 (zh)
WO (1) WO2000059517A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7993500A (en) * 1999-11-15 2001-05-30 New Millennium Pharmaceutical Research, Inc. Intranasal administration of raloxifene and tamoxifen
US6858383B2 (en) 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
KR100457113B1 (ko) * 2001-12-27 2004-11-16 한국원자력연구소 세라마이드류 또는 그 유도체와 다이메틸스핑고신을 유효성분으로 포함하는 방사선민감도 증진제
KR100459484B1 (ko) * 2002-05-20 2004-12-03 한국원자력연구소 엔-아세틸 파이토스핑고신과 다이메틸 파이토스핑고신을유효 성분으로 포함하는 방사선 치료 민감제 조성물
EP1610763A2 (en) * 2003-03-31 2006-01-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer
JP2008504330A (ja) * 2004-06-29 2008-02-14 ヤド テクノロジーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング スフィンゴ脂質由来医薬組成物
WO2006051549A2 (en) * 2004-11-15 2006-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
WO2007143175A2 (en) * 2006-06-02 2007-12-13 Roger Williams Hospital Combination of ceramide and oxaliplatin for inducing cell death and uses thereof in treating cancer
SI2087002T1 (sl) 2006-10-27 2014-11-28 Lpath, Inc. Sestavki in postopki za vezavo sfingozin-1-fosfata
US8216607B2 (en) * 2008-03-17 2012-07-10 Roger Williams Hospital Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
JP5649995B2 (ja) * 2011-01-31 2015-01-07 日本メナード化粧品株式会社 セラミド産生促進剤
WO2012125486A1 (en) * 2011-03-11 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination chemotherapy for treating cancer
WO2012138739A2 (en) 2011-04-06 2012-10-11 Chemo-Enhanced Llc Compositions and methods for treating cancer
CA2936345A1 (en) 2013-01-14 2014-07-17 Chemo-Enhanced Llc Compositions and methods for treating cancer
JP2017505301A (ja) * 2014-01-08 2017-02-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 転移性播種を予防又は低減するための方法及び医薬組成物
WO2017015301A1 (en) * 2015-07-20 2017-01-26 Rutgers, The State University Of New Jersey Ceramide derivatives as anticancer agents
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
US20170252311A1 (en) * 2016-03-02 2017-09-07 Signpath Pharma Inc. Sphingosine kinase inhibitors and ceramide for maintenance therapy of glioblastoma
US20220362177A1 (en) * 2019-10-16 2022-11-17 University Of Virginia Patent Foundation Ceramide ratios as predictive and therapeutic biomarkers for leukemias

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4787693A (en) * 1992-08-12 1994-03-15 Upjohn Company, The Protein kinase inhibitors and related compounds combined with taxol
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
ES2149350T3 (es) * 1994-02-02 2000-11-01 Liposome Co Inc Compuestos y liposomas farmaceuticamente activos y metodos para su utilizacion.
US5597830A (en) 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
JP2000510460A (ja) 1996-04-26 2000-08-15 マゲイニン・ファーマシューティカルズ・インコーポレーテッド スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療
US6841537B1 (en) * 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
JP2002541200A (ja) * 1999-04-14 2002-12-03 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の処置のための方法および組成物
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity

Also Published As

Publication number Publication date
US7015251B1 (en) 2006-03-21
AU4335400A (en) 2000-10-23
EP2020237B1 (en) 2013-12-18
WO2000059517A1 (en) 2000-10-12
EP2020237A2 (en) 2009-02-04
EP1206270A4 (en) 2004-04-07
EP2020237A3 (en) 2009-02-11
DK2020237T3 (en) 2014-03-17
US7820718B1 (en) 2010-10-26
EP1206270A1 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
HK1127912A1 (zh) 神經酰胺和化療藥物引致細胞死亡
EP1030912A4 (en) DEVICE FOR CELL SYSE
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
IL125631A0 (en) Halogenating agents and processes for the preparation thereof
IL128193A0 (en) Rhamnosyl-transferase gene and uses thereof
EP1004301A4 (en) PROMOTER OF PROTECTION AND SURVIVAL OF CELLS OF THE CENTRAL NERVOUS SYSTEM
SG70653A1 (en) Reassemblable reel and disassembly device
EP1222913A4 (en) EPILATOIRES AND AGENTS FOR EXTERNAL USE
GB9816144D0 (en) Load handling apparatus
HK1044947A1 (en) Benzamide derivatives and drugs containing the same
IL145711A0 (en) Thrombospondin-2 and uses thereof
HUP0002722A3 (en) Synergetic fungicidal mixture and use thereof
EP1071696A4 (en) PROGRAMMED CELL DEATH AND CASPASE-12
PL354184A1 (en) The prv-1 gene and use thereof
HUP0202163A2 (en) Methods of inducing cell death
GB9929581D0 (en) Comjpositions and their use
GB9930708D0 (en) MUS101 and homologues thereof
GB9818235D0 (en) Gene and use thereof
GB9908171D0 (en) Gene and use thereof
GB9817943D0 (en) Genostics and drugs
GB9814558D0 (en) Bggage etc handling
HU9802835D0 (en) Support for holding and arranging play cards
GB9421494D0 (en) Suspendible packs
GB9916402D0 (en) Orbit and homologues thereof
GB9930707D0 (en) Orbit and homologues thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180407